Evidence map›Paper›PMID 33512621›Full record

ArticleWiener medizinische Wochenschrift (1946)2021

New therapeutic options for bone diseases.

Roland Kocijan, Judith Haschka, Julia Feurstein, Jochen Zwerina

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Roland KocijanLudwig Boltzmann Institute of Osteology, Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, Heinrich-Collin-Straße 30, 1140, Vienna, Austria. roland.kocijan@osteologie.lbg.ac.at.
Judith HaschkaLudwig Boltzmann Institute of Osteology, Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, Heinrich-Collin-Straße 30, 1140, Vienna, Austria.
Julia FeursteinLudwig Boltzmann Institute of Osteology, Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, Heinrich-Collin-Straße 30, 1140, Vienna, Austria.
Jochen ZwerinaLudwig Boltzmann Institute of Osteology, Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, Heinrich-Collin-Straße 30, 1140, Vienna, Austria.
Hanusch Hospital · ATLudwig Boltzmann Institute of Osteology · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, new treatment options for both common and rare bone diseases have become available. The sclerostin antibody romosozumab is the most recently approved drug for the therapy of postmenopausal osteoporosis. Its anabolic capacity makes it a promising treatment option for severe osteoporosis. Other sclerostin antibodies for the treatment of rare bone diseases such as osteogenesis imperfecta are currently being investigated. For rare bone diseases such as X‑linked hypophosphatemia (XLH) and hypophosphatasia (HPP), specific therapies are now also available, showing promising data in children and adults with a severe disease course. However, long-term data are needed to assess a sustained benefit for patients.

Indexed as

Bone DiseasesHypophosphatasiaOsteoporosisOsteoporosis, PostmenopausalBone and BonesChildFemaleHumansAsfotase alfaBurosumabRare bone diseasesRomosozumabSclerostin antibody

Identifiers

PMID33512621
OpenAlexW3125864522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.